Call 877-883-0001 for all you CGM & Diabetic Supplies

Diabetes Info

Information for Diabetics

Diabetes is a chronic condition where the body cannot produce enough insulin or use it properly, leading to high blood sugar levels. This can result in serious health problems like heart disease, vision loss, and kidney damage. Managing diabetes requires lifestyle changes, medication and regular blood sugar monitoring. With proper care, people with diabetes can live healthy lives. Explore our resources for information on symptoms, treatments and management strategies.

Here's a detailed breakdown of diabetes prevalence across various racial and ethnic groups in the United States, segmented by age:

Non-Hispanic Whites:

Diabetes Prevalence: Among non-Hispanic Whites, roughly 7.5% of adults aged 20 and older have been diagnosed with diabetes, reflecting a significant health concern within this demographic.

Non-Hispanic Blacks:

Diabetes Prevalence: The prevalence of diabetes is notably higher among non-Hispanic Blacks, with approximately 12.1% of adults aged 20 and older diagnosed with the condition. This disparity underscores the need for targeted interventions and healthcare initiatives within this community.

Hispanics/Latinos:

Diabetes Prevalence: Among Hispanics/Latinos, an estimated 12.5% of adults aged 20 and older have been diagnosed with diabetes. This group faces unique cultural and socioeconomic factors that can impact their risk and management of the disease.

American Indians/Alaska Natives:

Diabetes Prevalence: American Indians/Alaska Natives exhibit one of the highest prevalence rates of diabetes, with around 14.7% of adults aged 20 and older diagnosed with the condition. Historical and systemic factors contribute to the disproportionate burden of diabetes within this population.

Asian Americans:

Diabetes Prevalence: While relatively lower compared to other racial and ethnic groups, diabetes still affects a notable portion of Asian Americans, with approximately 8.0% of adults aged 20 and older diagnosed with the disease.

Why do people in the US have a higher rate of diabetes than other countries?

The higher rate of diabetes in the United States compared to other countries can be attributed to several factors:

Diet and Lifestyle: The U.S. diet is often high in processed foods, sugars, and unhealthy fats, contributing to obesity, a major risk factor for diabetes. Sedentary lifestyles with limited physical activity further exacerbate this issue.
Obesity Epidemic: The U.S. has one of the highest rates of obesity in the world. Obesity significantly increases the risk of developing Type 2 diabetes, as excess body fat can lead to insulin resistance.
Socioeconomic Disparities: Socioeconomic factors play a crucial role. Many people in lower-income groups have limited access to healthy food options, safe areas for physical activity, and adequate healthcare, increasing their diabetes risk.
Healthcare System: While the U.S. has advanced medical technology, there are significant disparities in healthcare access and quality. Many individuals, particularly in underserved communities, lack regular access to preventive care and early diabetes management.
Genetic Factors: The U.S. is a melting pot of diverse ethnicities, some of which have a higher genetic predisposition to diabetes. For instance, non-Hispanic Blacks, Hispanics/Latinos, American Indians/Alaska Natives, and Asian Americans have higher diabetes rates compared to non-Hispanic Whites.
Awareness and Diagnosis: Higher rates of screening and diagnosis in the U.S. might lead to a greater number of reported cases. Increased awareness and medical testing can result in more individuals being diagnosed with diabetes than in countries with less comprehensive healthcare systems.
Urbanization and Technology: The prevalence of a modern, urbanized lifestyle with more sedentary jobs and greater reliance on technology can reduce daily physical activity levels, contributing to higher rates of obesity and diabetes.
Cultural Factors: Cultural norms and behaviors, including dietary preferences and attitudes toward exercise, can influence diabetes prevalence. The fast-paced lifestyle in the U.S. often leads to convenience eating and less time for physical activity.

These factors collectively contribute to the higher prevalence of diabetes in the United States compared to many other countries. Addressing these issues requires a multifaceted approach, including improving diet and lifestyle, increasing access to healthcare, and implementing public health initiatives to promote physical activity and healthy living.

Will the diabetes Epidemic in the US ever be fixed?

Addressing the diabetes epidemic in the United States remains particularly challenging due to the significant economic interests of companies that profit from diabetes treatments and related healthcare services. Major pharmaceutical companies like Novo Nordisk, Sanofi, and Eli Lilly generate substantial revenue from the sale of diabetes medications, insulin, and medical devices. For instance, Novo Nordisk reported over $18 billion in revenue in 2020, with a significant portion coming from diabetes care products. Similarly, Eli Lilly's diabetes segment, which includes popular medications like Humalog and Trulicity, contributed $5.8 billion in 2021.

These economic incentives can hinder efforts to implement widespread preventive measures and public health initiatives aimed at reducing the incidence of diabetes. The focus on developing and marketing new treatments for diabetes management often takes precedence over investing in preventive healthcare strategies that address the root causes of diabetes, such as obesity, poor diet, and sedentary lifestyles. This emphasis is reflected in the nearly $6.58 billion spent by the pharmaceutical industry on direct-to-consumer advertising in 2020, with a significant portion promoting diabetes drugs.

Additionally, the substantial profits generated from diabetes-related products influence policy and regulatory decisions. Lobbying efforts by pharmaceutical and healthcare companies significantly impact the development and implementation of policies designed to promote healthier lifestyles and reduce diabetes risk factors. In 2019, the pharmaceutical industry spent over $295 million on lobbying efforts in the United States, with companies like Sanofi and Eli Lilly actively involved. These companies often resist regulations that could negatively affect their profits, such as taxes on sugary beverages or restrictions on advertising unhealthy foods.

Despite these challenges, there have been recent policy changes aimed at reducing the economic burden of diabetes on patients. As of January 2024, the Inflation Reduction Act caps insulin cost-sharing at $35 per month for Medicare enrollees, including patients with commercial insurance. Additionally, Novo Nordisk offers a 30-day supply of insulin for $35 to eligible patients, including those without insurance. Eli Lilly has also announced 70% price reductions for its most commonly prescribed insulins and caps patient out-of-pocket costs at $35 per month or less.

While these steps help alleviate some of the financial strain on diabetes patients, addressing the root causes of the diabetes epidemic requires a comprehensive approach. This includes implementing policies that promote access to healthy foods, safe environments for physical activity, and equitable healthcare access for all communities. Overcoming the influence of economic interests necessitates strong leadership, public support, and collaborative efforts to prioritize public health over profit.

Page updated

Google Sites

Report abuse